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Abstract
The 20th International Symposium on HIV and Emerging Infectious Diseases took place in Marseille, France. It had a
refreshing European look with reinforced partnerships with the European AIDS Clinical Society and the British HIV Association
and with international speakers and participants. Topics included HIV and global health, HIV and hepatitis cure, the
microbiome and immunotherapies, clinical research and methodology, as well as chemsex, pre-exposure prophylaxis, sexually
transmitted infections and emerging infectious diseases. Novel areas of research were also described, such as electronic
technology in order to improve HIV management, and the expert patient.
Introduction
The 20th International Symposium on HIV and Emerging Infectious
Diseases (ISHEID) was held in Marseille, France and reinforced
partnerships with the European AIDS Clinical Society (EACS) and
the British HIV Association (BHIVA). Participants gathered from
all over the world for a rich programme on HIV and global health,
HIV and hepatitis cure, the microbiome and immunotherapies,
clinical research and methodology, as well as chemsex, pre-
exposure prophylaxis (PrEP), sexually transmitted infections (STIs),
electronic technology and emerging infections. It was an enriching
scientific experience thanks to the presence of, and dynamic
exchanges between, experts and younger investigators. In this
article we summarise the plenary sessions, keynote lectures, and
some of the oral presentations.
From HIV to global health
Stefano Vella (Istituto Superiore de la Sanità, Rome, Italy) gave
the inaugural presentation and spoke about HIV as a model of
global health, in order to fight health inequalities [1]. At least 30
million people die prematurely every year (half of them before
the age of 5) in developing countries from lack of adequate access
to basic healthcare and from often preventable or treatable
diseases. Despite the concept of health as a human right, there
still are intolerable global inequalities in terms of access to health
and healthcare services, life expectancy, morbidity and mortality
from communicable and non-communicable diseases. The
persistence of inequalities in terms of health – not only between
rich and poor countries, but also between different regions within
a country – is also a scientific contradiction given the growing
geographic interdependence of biomedical causes and social
determinants of health and diseases.
Global health includes the study, research, and actions that place
a priority on improving health and achieving health equality for
people worldwide, transcending perspectives and concerns of
individual nations (Figure 1). It emphasizes transnational health
issues, determinants and solutions, and involves many disciplines
within and beyond health sciences. It is a synthesis of population-
based prevention with individual-level clinical care and specific
attention to the poor, marginalised and underserved.
The way the HIV pandemic has been addressed, despite still being
an unfinished job, may be a model to fight wider health
inequalities. Indeed, HIV/AIDS drew together, with the common
objective of fighting a major health inequality, scientists, clinicians,
governments, the United Nations, visionary politicians, economists,
international organisations, the pharmaceutical industry, both
proprietary and generics, NGOs, faith based- and patient
organisations [2]. It has recognised the supranational character
of tackling diseases and the fact that no individual country can
on its own address diseases in the face of the migration of people,
trade, microbes and risks for disease acquisition. It has mobilised
innovative drug production, pricing and procurement, both from
generic and proprietary manufacturers. It also has recognised that
people affected by disease have a crucial role in the advocacy for
new types of treatment and prevention and their equitable access
[3]. It has based its action on ethical and moral values that
recognise that equity and rights are central to the larger goals
of preventing and treating diseases worldwide.
What‘s up in HIV?
Beatriz Mothe Pujadas (Hospital Germans Trias i Pujol, Barcelona,
Spain) overviewed current strategies for therapeutic HIV vaccines.
Functional HIV cure still seems not immediately achievable.
However, recent ‘kick and kill’ trials such as the BCN 02 study
combining a potent T cell vaccine with a latency-reversal agent
(LRA), have suggested that viral control may be achieved by an
effective redirection of cytotoxic T lymphocytes (CTL) towards
conserved regions of the virus in the context of an early treatment
intervention with antiretroviral therapy (ART) (>Fiebig stages III–IV)
and limited viral reservoir (Figure 2) [4].
Sofie Rutsaert (Ghent University, Ghent, Belgium) presented
evidence for total HIV-1 DNA threshold as a guide for treatment
simplification strategies [6]. Although triple ART is the
recommended initial treatment, therapy simplification with a
reduced number of drugs is being explored. Fewer drugs can
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reduce cost, avoid drug–drug interactions, improve tolerability and
decrease toxicity in terms of lifelong treatment. Total HIV-1 DNA,
which reflects the number of infected cells in treated individuals,
can aid in selecting eligible patients. A significantly higher level
of HIV-1 DNA is observed in patients whose treatment fails
virologically while on a simplified regimen, when compared to
patients who maintain an undetectable viral load. This has been
observed with various regimens (darunavir/r monotherapy,
raltegravir/etravirine) and indicates that total HIV DNA is very
informative in terms of treatment strategies, even if its predictive
value remains yet to be proven [7] (Rutsaert et al., submitted).
However, to be clinically useful, this observation will have to be
confirmed with a long-term follow-up of patients and other
regimens, such as dolutegravir/lamivudine, dolutegravir
monotherapy (Wijting and Rutsaert, submitted) or dolutegravir/
rilpivirine therapy.
Chloe Orkin (Barts Health NHS Trust, London, UK) argued for
two-drug therapy (2DR) as a treatment and management strategy
to reduce toxicity and ART exposure, using new agents or different
ART formulations. Switching to 2DR in a virologically suppressed
patient should be done safely and for a good reason, after review
of ART history, genotype, interactions and possible co-infections.
There are knowledge gaps regarding 2DR that include a lack of
Figure 1. Global health targets
Figure 2. Target population for early phase clinical trials: acute and recent HIV infection. Adapted from [5]
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long-term data, hepatitis B co-infection, high viral loads, low CD4
T cell counts, resistance mutations, HIV viral reservoir
measurements, pregnancy and chronic inflammation. Ongoing
issues include the adherence level necessary to maintain virological
control, frequency of virological monitoring for 2DR, if relevant
for those with unclear genotypic history, and options for salvage
in the case of virological failure on 2DR treatment.
Emerging infectious diseases
Frederic Bartumeus (Blanes Advanced Study Centre, Girona,
Spain) described the organisation of a Platform for the Integrated
Control of Arbovirosis in CATalonia (PICAT): Mosquito Alert 2.0
[8]. Traditional methods for tracking disease-carrying mosquitoes
are hitting budget constraints because the scale over which they
must be implemented is growing exponentially. Citizen science
offers a set of innovative tools for public health management,
allowing sustained and flexible data collection while facilitating
public participation in problem solving [9,10]. There is increasing
evidence that combining citizen scientist data with other sources
of information significantly improves our knowledge in a given
area [11]. In particular, once we adjust for sampling bias, vector
data obtained through the Mosquito Alert citizen science
programme has almost the same quality and predictive power as
that obtained through traditional surveillance. Vector data is now
being further integrated with epidemiological and socially relevant
data into a digital platform to augment the information already
available from public health sources and to provide risk models
and key information to public health authorities at near real-time.
The scientific exploitation of citizen science programmes and big
data solutions should effectively help to reduce the presence of
targeted mosquitoes and minimise current health threats.
Jean-Paul Gonzalez (Center of Excellence for Emerging and
Zoonotic Animal Diseases, Manhattan, Kansas, USA) gave a
passionate talk about climate change, socio-political changes and
emerging pandemics [12]. Hippocrates, in his treatise ‘On Airs,
Waters, and Places’, written almost 2500 years ago, shows us the
links that exist between environment and health. Indeed, many
communicable diseases are known to be climate-dependent (e.g.
vector-borne diseases, seasonal flu, meningoencephalitis), and
certain degenerative diseases can be influenced by climatic factors
(e.g. neurodegenerative and, rheumatic diseases). Currently, the
effects of greenhouse gas emissions and climate change on health
can be seen in the resurgence of certain infections. Following on
from a ‘One Health’ approach, some exemplary epidemic events
were presented, for example the seasonality of the microbiome
[13], which provides the necessary fundamentals for the
understanding of climate change, extreme climatic events, their
impact on health and, how to be prepared and respond.
What about hepatitis cure?
The liver is one of the major anatomical sites targeted in HIV
infection, mostly as result of frequent co-infection with hepatitis
viruses and/or hepatotoxicity associated with lifelong ART
exposure. In addition, the prevalence of fatty liver disease is rising
in this population as successfully treated individuals live longer,
while frequently experiencing metabolic complications [14].
Several presentations addressed the current burden of viral and
non-viral liver events, comparing trends in those living with HIV
and the general population.
Hepatitis A
Hepatitis A virus (HAV) is a small RNA agent predominantly
transmitted via the faecal–oral route from contaminated food and
water, or from person to person. The mean incubation period is
1 month. Acute HAV is always self-limited, very rarely fatal, and
does not progress to chronicity. Acutely infected persons are most
likely to transmit the virus before the onset of jaundice, when the
concentration of viral particles in stools is highest. Hepatitis A is
a vaccine-preventable disease, although universal childhood
vaccination is not mandatory in most Western countries. In adults,
vaccination is generally recommended for men who have sex with
men (MSM) and injecting drug users (IDUs) as well as in travellers
to regions where it is endemic such as Latin America, Africa and
Asia. In the European Union and North America almost all
infections are directly or indirectly imported.
Olga Tsachouridou (AHEPA University Hospital, Thessaloniki,
Greece) presented a study on 1210 adults living with HIV who
attended hospital during the last decade [15]. Natural immunity
to HAV was recognised in 338 (28%) individuals. Vaccination was
recommended to those non-immune. Of 203 who received only
a single dose, protective antibody titres (>20 IU/mL) were achieved
by 71%. It increased to 81% for those who completed the
two-dose vaccination schedule. Patients immunised during the
peak of the financial crisis in Greece (2010-2015) and IDUs
frequently missed the booster dose. Altogether, this data supports
testing for HAV antibodies in all individuals living with HIV,
acknowledging that 20% may not respond with protective
antibodies, even following the second vaccine dose.
Transmission of HAV through sexual contact, particularly in MSM,
as well as through sharing of needles and syringes has been the
subject of a recent alert in several European countries, with
outbreaks among MSM in the UK, Germany, Portugal, Italy and
Spain [16]. It highlights the interconnectedness of MSM and the
need to increase HAV vaccine coverage within this group. Of note,
the recent shortage of HAV vaccine is partially contributing to
the lack of control of the ongoing HAV epidemic in Western
countries. Although HIV infection does not seem to increase
susceptibility to HAV, and liver enzyme elevations tend to be milder
in this group, a high rate of concomitant sexually transmitted
infections (STIs), including syphilis, chlamydia and gonorrhoea,
has been reported. The alarming rising incidence of STIs among
MSM occurs regardless of HIV status, as highlighted at ISHEID
by French investigators [17].
In summary, MSM are at particular risk for HAV infection and there
is a need for proper information and education on safe sexual
behaviour, including personal hygiene measures before and after
sexual contact. Immunisation rates against HAV should be
increased in this population, as well as post-exposure prophylaxis
to close contacts (active and passive immunisation is effective if
administered within 2 weeks of exposure). Finally, it was noted
that it is important to exclude other sexually transmitted diseases
in those with acute HAV.
Hepatitis B
The major pandemics caused by chronic viral infections involve
HIV, hepatitis C (HCV) and hepatitis B virus (HBV), with estimates
of 38, 70 and 250 million affected people worldwide, respectively
(Figure 3). In the past few years, the advent of direct-acting oral
antivirals for HCV treatment has led to plans for global eradication.
These new drugs cure more than 95% of cases of HCV when given
for only 2–3 months [18]. This breakthrough has resulted in
renewed interest in finding curative strategies for both HIV and
HBV. However, important biological differences between these
viruses may preclude such rapid success.
Once HCV enters into hepatocytes, its viral genetic material
replicates within the cytosol whereas HIV integrates into
chromosomes as provirus and HBV is converted into a circular
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covalently closed form (cccDNA) [19]. Blocking viral nucleic acid
replication for a length of time allows definitive clearance of HCV
infection, with degradation of residual cytoplasmic HCV RNA
strands. In contrast, given the stability of the HIV provirus and
HBV cccDNA, blocking viral replication has only a transient effect
as mRNA expression resumes following treatment discontinuation.
Vicente Soriano (Hospital Carlos III, Madrid, Spain) gave an
update on the new therapeutic strategies against HBV. The
achievement of a functional cure with clearance of serum HBsAg
will be the next step in the path to finding a cure. Ultimately this
will require the elimination of the reservoirs of cccDNA and
chromosomic integrated HBV DNA [20]. Presently, it seems that
a combination of antivirals and immune modulators may be the
best way forward. Several antivirals that target different steps of
the HBV replicative cycle are being tested (Figure 4), including
entry inhibitors (e.g. Myrcludex B), transcription inhibitors (RNA
interference molecules such as ARO-HBV), capsid assembly
inhibitors (e.g. JNJ-379), and nucleic acid polymers (NAPs) that
inhibit HBsAg release (e.g. REP 2139). Alongside antivirals, several
immunological agents are being evaluated (Table 1).
When considering the pros and cons of novel
HBV therapeutic candidates, HBV gene
therapies are among the most attractive ones.
Several advances have contributed to position
gene therapy at the forefront of the
experimental HBV armamentarium. First,
progress in delivery systems, including the use
of polymers and nano formulations, has
allowed the development of subcutaneous
and monthly treatments that are easier
to administer. Synthetic production of
oligonucleotide formulations has reduced
costs. Their specificity against HBV is higher
than other experimental agents: toll-like
receptor (TLR) agonists (e.g. GS-9620) or
check point inhibitors (e.g. nivolumab) are
immune modulators that enhance innate
immunity. Significant declines in serum HBsAg
are demonstrated during gene therapy that
have never been seen using the most potent
polymerase inhibitors (e.g. tenofovir or
entecavir). Lastly, unanticipated significant reductions in cccDNA
are seen with HBV gene therapy, most likely as a result of an
indirect benefit in reducing the immunosuppressive effect of large
amounts of HBsAg released by infected hepatocytes that
contributes to T cell exhaustion.
Hepatitis C and NASH
The unprecedented success of direct-acting antivirals (DAAs), which
achieve an HCV cure in most treated individuals, has shifted the
attention to other frequent conditions in this population. There
is a need to continue monitoring and screening for hepatocellular
carcinoma in patients with cirrhosis who have been cured of HCV
[21]. Another frequently associated condition is fatty liver disease.
Laurence Serfaty (Hautepierre Hospital, Strasbourg, France)
addressed this issue, beginning with a review of the interplay
between lipids and HCV, and how HCV cure may unveil metabolic
abnormalities which, if not managed properly, may lead to
progressive liver disease despite HCV elimination. Non-alcoholic
liver disease (NAFLD) and steatohepatitis (NASH) are very
prevalent and directly associated with overweight/obesity and
Figure 3. Major chronic viral pandemics
Table 1. The new HBV armamentarium
Mechanism Drugs
Antivirals (life cycle) Entry inhibitors Myrcludex B
cccDNA cleavage
(gene editing)
CRISPR/cas9, TALENS, ZFNs
Transcription
inhibitors (RNA
interference)
ARC-520, ARO-HBV, ARB-1740, AB-729,
ALN-HBV, TKM-HBV
RG-7834
Polymerase
inhibitors
TAF, CMX-157, AGX-1009, besifovir,
lagociclovir
Capsid blockers GLS-4, NVR 3-778, JNJ-379
Release inhibitors Rep-2139, Rep-2165
Immune modulators
(immunity)
Innate immunity • TLR-agonists (GS-9620)
• Anti-PD1 (nivolumab)
Adaptive immunity • Therapeutic vaccines (GS-4774, TG-1050)
• Engineered T cells
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sedentary life style [22]. To date, there is no good drug therapy
to treat NASH, which unfortunately is becoming the predominant
cause of cirrhosis, end-stage liver disease and liver transplantation
in Western countries.
Hepatitis D
Hepatitis delta virus (HDV) is the smallest pathogenic agent that
infects humans. However, it causes the most severe form of viral
hepatitis, with frequent progression to cirrhosis and liver cancer
[23]. To date there is no efficacious treatment against HDV,
although anecdotal cases of benefit using tenofovir have been
reported [24] and promising new experimental drugs are in
development [25].
To complete its replicative cycle, HDV requires the presence of
HBsAg, which is incorporated within the HDV envelope. Acute dual
HBV and HDV co-infection may be clinically severe, sometimes
presenting with fulminant hepatitis, but generally self-limited with
development of antibodies and clearance of both viruses. In
contrast, HDV superinfection of HBsAg+ carriers generally
progresses to chronicity. Roughly 5% of the 240 million people
with chronic HBV worldwide are estimated to be superinfected
with HDV [26]. The decline in injection drug use in Western
countries has driven a reduction in HDV incidence [27]; however,
the growing opioid epidemic in the United States and rising
‘slamsex’ practices in Europe are challenging this trend [28].
The diagnosis of HDV infection is generally based on the
demonstration of HDV antibodies (HDV-Ab) in HBsAg+ individuals.
Serum HDV-RNA can be found in most chronic HBsAg+ carriers
with reactive HDV-Ab, although with frequent significant
fluctuations. Information on the rate and clinical relevance of
HDV-Ab in persons with markers of resolved HBV infection is rather
scarce. Presumably, this population should reflect past acute dual
co-infection episodes. However, some of these individuals may
present with elevated liver enzymes and/or significant hepatic
fibrosis, opening the question of the existence of HBsAg-
seronegative occult HDV infections.
Carmen de Mendoza (Puerta de Hierro University Hospital,
Madrid, Spain) discussed this topic [29]. In her study, sera from
406 individuals with markers of resolved HBV infection were tested
for HDV-Ab, of which 20 (5%) were reactive. All of them were
repeatedly negative for HDV-RNA, despite four displaying elevated
liver enzymes. A retrospective investigation showed that three
individuals had concomitant chronic HCV and one admitted high
alcohol intake. She concluded that active HDV infection is not
seen in patients with reactive HDV-Ab and markers of past HBV
exposure [24]. These results reinforce the notion of a self-limited
outcome following dual acute HBV and HDV co-infection and
support the current policy of excluding HDV only in HBsAg+
individuals.
Chemsex
This year the subject of chemsex was covered during the first
collaborative symposium between the European AIDS Clinical
Society (EACS) and ISHEID.
Dominic Rowley (Saint James Hospital, Dublin, Ireland) presented
on the whole new world of synergy between geo-sexual
networking and recreational drugs (gammahydroxybutyrate or GHB
or G, synthetic cathinones, crystal metamphetamine) that define
a syndemic of specific behaviours and STI outbreaks worldwide.
Chemsex practices have increased in prevalence over the past
decade, especially in the MSM population, and are becoming a
real public health problem. The concerns about these practices
are not only related to their high toxicity (cardiovascular,
psychological), which remain largely unknown and underestimated
by consumers, but are also related to the increased prevalence
of STIs and the risk of HIV acquisition. Dr Rowley described the
new ‘MTV generation’ [30], those using methamphetamine,
Truvada and Viagra to enhance sex and stay safe. The MISI (MSM
Internet Survey Ireland) 2015 reports that in more than 3000
participants interviewed, 7% used chemsex during the previous
year. Drugs used included ketamine, mephedrone, crystal meth
and G, and were more often used by men with higher education,
HIV seropositive status and aged under 30. In the GMHS, Ireland‘s
only MSM-specific sexual health clinic, 27% of persons interviewed
(486 questionnaires) had engaged in chemsex, and 56% of
respondents met their partners for chemsex through phone apps
or online. Chemsex was associated with more partners, unprotected
anal intercourse, having ever been diagnosed for a STI, and having
ever been treated for an STI or HIV. However, 30% asked for help
Figure 4. Major HBV therapeutic targets
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or advice regarding chemsex. Direct drug-related harm may include
polydrug use, injecting drug use, loss of consciousness and
potential for addiction. Indirect drug-related harms include sexual
risk-taking behaviours, increased risk of STIs and HIV, mental harms
(depression, psychotic episodes, suicidal tendencies) as well as
a negative impact in their lives (high financial burden, losing sense
of time, loss of career, social isolation). These results support
international evidence for a growing chemsex culture among MSM
and reinforce the need for developing educational programmes/
training courses around chemsex, aimed at not only users but also
healthcare professionals in order to help manage this
underestimated addiction, which is becoming a significant public
health issue.
Viken Darakjian (Positive People Armenian Network Social NGO,
Yerevan, Armenia) gave an overview of the current status of
chemsex practices in Europe and presented chemsex from the
community perspective. Chemsex is more common in the gay
community, probably more in HIV-infected and younger MSM, with
a higher prevalence in major Western European cities (see the
European MSM Internet Survey (EMIS) 2016). This practice has
appeared more recently in Eastern Europe but may be
underestimated owing to stigma and discrimination in some
countries. Different surveys carried out in France (25% of Hornet
users are engaged in chemsex, of whom 7% engage several times
a week), Ukraine and Armenia report that the major reasons for
starting chemsex use are environmental and linked to their partner
(already using it or in a ‘party’ context), or through curiosity. The
main reason for continuing is related to the improvement (pleasure,
potential) in their sexual life. Drug services and healthcare providers
across Europe struggle to offer appropriate support because of
a lack of expertise around chemsex and social media apps, as well
as prejudice around drug use and gay sex. Sexual health
professionals should learn to discuss sex and drugs with their MSM
patients. Therefore, there is an urgent need for developing a
chemsex care plan, involving both social and health professional
communities, to help people who want to come out of the chemsex
scene, and to work on harm reduction. Data collected during the
European MSM Internet Survey (EMIS) 2017 will provide up-to-
date information on the prevalence of chemsex across Europe,
and will allow identification of priority target groups for
interventions.
Zoë Greenwald (L’Actuel Medical Clinic, Montreal, Canada)
presented results of a retrospective study carried out in 1881 MSM
from their cohort, evaluating chemsex use and STI incidence among
PrEP users [31]. Overall, 28% of MSM were chemsex users (most
common drugs used were GHB/GBL and ecstasy) and they were
significantly younger (35 versus 37.6 years), had more partners
within the past 12 months (34 versus 28), a lower education level
and an income <€23,000 (35% versus 30%), and using daily more
frequently than intermittent PreP (84% versus 78%) compared
to non-chemsex users. Chemsex users experienced significantly
higher 12-month cumulative STI risk (44.3% versus 34.6%) and
cumulative rate of gonorrhoea (35.7% versus 21.3%) that
corresponded to a 48% increased STI risk (RR 1.48, 95%CI
1.20–1.82). In conclusion, this study reported chemsex
consumption in a high proportion of PrEP users, which may
contribute to increased STI risk and highlights the urgent need
for implementing counselling and combined prevention measures
to minimise the potential harms associated with its use.
Lyme disease
Christian Perronne (Raymond Poincaré Hospital, Garches, France)
gave a thought-provoking overview of Lyme disease, the tick-borne
borreliosis infection that was first described more than 30 years
ago in the north-eastern part of the USA as a new rare regional
event [32]. However, it is likely to have been present more than
5000 years ago. Professor Perronne described the associated
clinical manifestations and stressed the pitfalls in terms of diagnosis
and treatment in a context of increased incidence of the infection
in many parts of Europe but with a lack of standardised surveillance
reporting procedures [33].
The diagnosis of Lyme disease remains difficult as it mimics many
other medical conditions and laboratory tests do not always permit
confirmation of the diagnosis [34,35]. Furthermore, the initial bite
is not always reported by affected individuals and the rash
(erythema migrans) can be atypical. Untreated Lyme disease can
produce a wide range of symptoms depending on the stage of
the disease. Ticks can also spread several other organisms that
may cause different types of rash. Stages 2 and 3 of the illness,
coming weeks or months later, encompass symptoms such as
high-grade fatigue, migrating pain, chronic signs and symptoms,
often objective, but not specific, cutaneous, neurological,
ophthalmological, psychiatric, articular, musculo-skeletal and
cardiac, as well as auto-immune syndromes. Issues remain with
commercial diagnostic tests that are not considered totally reliable
in establishing the diagnosis and need to be supplemented by
clinical data.
Persistence of symptoms after the initial standard antibiotic
treatment may require a longer period of treatment. Professor
Perronne cited randomised studies published in the New England
Journal of Medicine with a longer duration of treatment that have
brought negative results [36,37]. These have methodological issues
and were therefore considered by him as non-conclusive. There
is still a lack of trials looking at a very prolonged period of
treatment and its impact on symptoms. Professor Perrone urged
for urgent research in diagnostics and therapy.
The microbiome
Sergio Serrano (Ramon y Cajal Hospital, Madrid, Spain) gave a
presentation on considering the microbiota as an ecosystem [38].
Blood microbiota may play a crucial role in HIV/SIV pathogenesis,
and in individuals living with HIV, there is a blood microbiota
signature that is linked with immune recovery and inflammation
under ART [39], as well as vaccine immunogenicity. Genital
microbiota not only influence the risk of HIV acquisition in men
and women [40] but may also determine the effectiveness of
tenofovir gel against HIV (Figure 5) [41]. The lung microbiome
is related to bacterial infection [42] and tuberculosis susceptibility
and could affect the risk of pulmonary diseases in HIV, such as
chronic obstructive pulmonary disease and lung cancer. He
suggested that HIV, HPV and microbiota may be partners in the
crime of HPV-related cancers in HIV, because epithelium-adherent
microbiota (anal, cervical or oral) may promote HPV malignant
transformation [43]. Microbiota-oriented precision medicine may
offer an opportunity for personalised medicine, even if results so
far have been inconclusive in individuals living with HIV.
New pathways for HIV cure
Ole Schmeltz Søgaard (Aarhus University, Aarhus, Denmark)
discussed ‘shock and kill’ versus ‘block and lock’ strategies.
Although many LRAs have been tested in clinical trials (Table 2),
their impact on the size of the reservoir has been disappointing
[44,45]. Either the ‘shock’ has been too weak, reactivating too
few infected cells (suggesting the need for LRA combinations),
or the ‘kill’ does not occur in vivo owing to inadequate immune
responses. Therefore, ‘shock and kill’ as a strategy for a sterilising
HIV cure will be very difficult to achieve with the current portfolio
of compounds. The timing of therapeutic interventions relative
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to ART may impact both the reservoir and immune functions. The
‘block and lock’ strategy (Figure 6) is a more recent development
and is currently using a Tat inhibitor (didehydro-cortistatin A or
dCA) that has been tested in cell culture and humanised mice;
however, the safety profile in humans is unknown [46].
Christina Psomas (European Hospital, Marseille, France) presented
perspectives of new markers of HIV latency. The ‘Holy Grail’ of
the HIV world is to identify a marker that could characterise latently
infected cells. Indeed, these latently infected long-lived memory
CD4+ T cells are the major obstacle for achieving a sterilising cure.
They not only remain invisible to the immune system but are also
not removed by antiretroviral therapy and cure approaches because
of a lack of targeting specificity of ‘shock and kill’ strategies
involving reactivation of the dormant virus. In a recent Nature
article, Descours et al. reported that CD32a, the low-affinity
receptor for the immunoglobulin G Fc fragment may be a cell
surface signature of CD4+ T cells harbouring latent HIV genomes
[48]. Since then, the relationship between CD32a expression and
HIV persistence has been strongly debated by other groups. Will
this biomarker help us address the mystery surrounding in vivo
latent reservoirs and develop a cure-focused HIV diagnostic in the
near future? Will newer biomarkers such as CD30 be less debated
and more helpful [49]?
Therapeutic management of comorbid diseases
During this morning session, Patrick Mallon (University College
Dublin School of Medicine, Dublin, Ireland) gave an overview of
bone disorders. Several factors are involved such as the increased
number of individuals living with HIV reaching the age at which
bone issues occur, the fact that low bone mineral density (BMD)
is more prevalent in people living with HIV in comparison to the
general population with similar demographic characteristics and
the available evidence showing an increased risk of fractures in
those living with HIV regardless of age.
Figure 5. Genital microbiota and HIV transmission
Table 2. LRAs tested in clinical trials
Latency
reversing
agent
Drug class Effect on
transcription
in CD4s
Single or
Multi-dose
study
US HIV RNA
(transcription)
HIV
protein
expression
Plasma HIV
RNA (SCA
or TMA)
Plasma
HIV RNA
(Cobas)
Reference (s)
Vorinostat HDACi Direct S+M ++ + + - Archin et al. 2012, 2014,
2017; Elliott et al. 2015
Panobinostat HDACi Direct M ++ + + ND Rasmussen et al. 2014
Romidepsin HDACi Direct (S)+M ++ ND ++ + Søgaard et al. 2015; Leth
et al. 2016
Disulfiram Anti-alcohol Direct M + ND + - Spivak et al. 2014; Elliott
et al. 2015
Bryostatin Protein Kinase C
(PKC) activator
Direct S - ND - - Gutiérrez et al. 2016
MGN1703 TLR9 agonist Via pDCs M - ND ND (+) Vibholm et al. 2017
GS-9620 TLR7 agonist Via pDCs M ? ? ? ? ?
Figure 6. Principles of the block and lock strategy [46]
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With a practical clinical point of view, Dr Mallon structured this
topic into three parts: prevention, reversion of BMD loss and some
tips for maintaining bone health.
Regarding prevention, he stressed the need for systematic
screening for low BMD by performing DEXA scans. The EACS
guidelines suggest DEXA scans in high-risk patients:
postmenopausal women, men over 50 years of age, those under
the age of 50 at high risk for fractures, patients with risk factors
for falls, those with past history of low impact fractures, clinical
hypogonadism, and those with significant steroid exposure.
Initiation of ART is associated with a BMD loss of between 2%
and 5%, irrespective of the regimen, and is similar to that observed
after menopause. The degree of BMD loss in ART-experienced
patients after re-initiation of ART (demonstrated in the Second-
Line study) is similar to what is observed with first line treatment.
For reversion of BMD loss, Dr Mallon reviewed the different effects
of ART on BMD. Data from several clinical trials demonstrates the
negative effects on BMD of tenofovir disoproxil fumarate (TDF)
and protease inhibitor-based regimens in ART-naïve patients.
Switching from TDF to tenofovir alafenamide (TAF) produces
increments in BMD of around 1.5%. Other strategies such as giving
calcium and vitamin D supplements or bisphosphonates during
ART initiation have proved useful in ameliorating the initial BMD
loss. There is less evidence on the effect of switching away from
TDF-based regimens in the long term. Data from some cohorts
such as the HIV-UPBEAT demonstrate that the initial decay of
BMD after ART tended to stabilise in the long term.
Dr Mallon suggested strategies other than pharmacological
interventions for maintaining bone health in the long term:
strengthening physical exercise, lowering immune activation (future
area of research) and in particular, smoking cessation. He explained
that in the HIV-UPBEAT cohort the statistically significant
association found between bone microarchitecture, measured by
trabecular bone score (TBS), and HIV disappeared after adjusting
for smoking status, highlighting the importance of this issue.
Rosan van Zoest (Institute for Global Health and Development,
Amsterdam, the Netherlands) discussed the new challenges of
comorbidities. This topic is directly derived from the happy fact
that, as a consequence of effective ART, people living with HIV
have a similar life expectancy as those in the general population.
A modelling study from the Netherlands shows that 73% of those
living with HIV will be over 50 years in 2030. This will imply a
high burden of comorbidities and multimorbidity, with this trend
likely to increase over time. Recent reports highlight the increased
frequency of comorbidities in people living with HIV in comparison
with HIV-negative controls, especially with respect to cardiovascular
(CV) diseases, some non-AIDS-related cancers and chronic kidney
disease. The ultimate cause of this is multifactorial. The higher
prevalence of some traditional CV risk factors such as smoking,
dyslipidaemia or hypertension is a critical issue. Among these,
tobacco use is the one that deserves most attention as several
studies have suggested that the relationship between smoking
and comorbidities, in particular, CV disease, may be stronger in
HIV-positive individuals compared with the general population.
Platelet dysfunction, endothelial-cell activation, low-grade immune
activation, and inflammation, in spite of effective ART, are likely
to be involved in the higher comorbidity burden in people living
with HIV. Rosan van Zoest concluded that several strategies could
be used to reduce the burden of comorbidities in those living with
HIV, including prompt HIV diagnoses and early ART initiation,
avoidance of certain HIV agents with some toxic side-effects in
both the short and long term, and a more aggressive management
of traditional risk factors for comorbidities.
Jean-Pierre Routy (McGill University, Montréal, Canada) reviewed
the interplay between HIV infection and lungs, focusing specifically
on lung cancer [50]. It is the most frequently diagnosed non-AIDS
cancer in people living with HIV and the only increasing one with
a non-infectious cause. Several risk factors have been put forward:
smoking, history of bacterial pneumonia and a low CD4: CD8 ratio.
Lung infections promote some metabolic and epigenetic changes
in innate immune cells located in the lungs, which result in
enhanced immune responses upon re-infection. This trained innate
immunity could inappropriately activate inflammatory pathways
in the long term and increase the risk for lung cancer.
Professor Routy also presented data on specific characteristics of
lung cancer in people living with HIV. Data from a Canadian study
showed an increased mortality in patients with non-small-cell lung
cancer in comparison with the general population. A recent
systematic review and meta-analysis, including different types of
lung cancer, also suggest a higher mortality for patients with HIV
and lung cancer [51]. A recent revolution in medicine involves
immunotherapy against cancer with anti-PD1/PD-L1 antibodies
that have shown high efficacy against different types of cancer.
These drugs are promising. Recent data have demonstrated a
higher expression of PD-L1 levels with increased immune
infiltration in samples from patients with HIV and lung cancer [52].
This should encourage further investigation and the commitment
from pharma companies not to systematically exclude people living
with HIV from clinical trials testing these new immune therapies.
Finally, an intriguing discovery: the gut microbiota influences the
response to PD-1-based therapies against different epithelial
tumours and could explain resistance to some of these drugs.
After these excellent plenaries, there were two oral presentations
on environmental exposures and airflow obstruction, and the
impact on the lipid profile of switching to TAF. Cecilia Costiniuk
(McGill University Health Centre, Chronic Viral Illness Service,
Montreal, Canada) [53] underscored the importance of COPD with
a prevalence of 11% in people living with HIV according to a recent
meta-analysis published in Lancet Global Health [54]. Dr Costiniuk
presented a cross-sectional study in 508 participants, 95% on ART,
and 92% with suppressed HIV viral load.
Spirometry was performed in all participants and an extensive
questionnaire about environmental/occupational exposure was
completed. The authors found an 11% prevalence of airflow
obstruction defined by a FEV1/FVC <70% post-bronchodilator.
Smoking and older age were independent predictors of non-
reversible airflow obstruction but environmental or occupational
exposure was not associated with non-reversible airflow
obstruction.
In the final oral presentation Aoife Lacey (University College
Dublin, School of Medicine, HIV Molecular Research Group, Dublin,
Ireland) presented the results of a retrospective study that showed
changes in the lipid profile following switch from a TDF- to
TAF-containing regimen [55]. They compared pre- and post-switch
lipid data in 194 patients. Baseline characteristics of the
participants were a medan age of 46 years, 70.6% were male and
70% white. Median CD4 T cell count was 621 cells/mm3, 90%
had an undetectable viral load (HIV-1 RNA <40 copies/mL), 23.7%
were on lipid-lowering drugs, and 87.8% had TAF as a backbone.
Significant increases in all lipid fractions were observed (total
cholesterol, LDL cholesterol, HDL cholesterol, triglycerides and
TC: HDL ratio). Using the recent definition of dyslipidaemia
according to the ATP III guidelines thresholds, a greater proportion
of participants met this definition especially for total cholesterol
and LDL cholesterol. The authors concluded that further studies
are needed to ascertain whether these differences are a
consequence of TDF cessation or TAF initiation.
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Immunotherapies and immune check-points
Jean-Philippe Spano (Pitié-Salpêtrière Hospital, Paris, France)
gave an overview of this very fast emerging new therapeutic
approach in oncology [56]. For a wide spectrum of malignancies,
the use of PD-1 or PD-L1 and/or CTL-4 immune-checkpoint-
inhibitor antibody (ICI) that restores antitumor immunity by
disrupting PD-1/PD-L1 or CTL-4-mediated signalling has
demonstrated efficacy compared with conventional chemotherapy
but also a significant toxicity profile. Since several Phase 3 studies
show a significant impact upon overall survival compared with
conventional chemotherapy, some ICIs (ipilimumab, nivolumab,
pembrolizumab, atezolizumab, darvelumab) have already received
FDA and/or EMA approval, providing a new standard of care for
some cancer patients. PD-1 receptor for example, which is
expressed on activated T cells, in link with ligands PD-L1 and
PD-L2 expressed in tumour cells, remains the cornerstone for the
rational for the development of such drugs. In the HIV setting,
PD-1 expression on HIV-specific T cells is associated with T cell
exhaustion and some preclinical studies have suggested that
blocking the PD-1/PD-L1 axis with monoclonal antibodies would
be of interest in HIV-associated lymphoma and possibly other
cancers.
Workshop on STIs
Dominique Tessier (PEP Clinic, Centre Hospitalier de l’Université
de Montréal, Montreal, Canada) presented results of PrEP
consultations at L’Actuel/CMUQL. Over 1500 patients have already
been enrolled in their PrEP programme. The entire team is
committed to standardised follow-up, prescription and data
collection. Until recently, only Quebec had offered public
reimbursement for PrEP. Elsewhere, individuals wishing to use PrEP
had been limited to coverage via private third-party insurance,
or through use of so-called ‘buyers’ clubs, which promote access
via online pharmacies. Positive PrEP consequences principally
include a 90% decrease in HIV incidence, after a discouraging
increase in new HIV cases in 2015. Negative PrEP consequences
include failures (HIV seroconversion at the beginning of PrEP or
after it has been stopped), ‘pretend to be on PrEP’ issues, and
an increase in STI diagnoses and treatment. This last point still
requires analysis to see whether it involves a net increase in
acquired STIs or early diagnosis in the context of PrEP programmes.
Deborah Konopnicki (Saint Pierre University Hospital, Brussels,
Belgium) discussed HPV vaccination in prevention and cure [57].
Human papillomaviruses (HPV) are responsible for the development
of condyloma and cancer in the ano-genital and oropharyngal areas
(Figure 7). These lesions are more frequent and more difficult to
treat in HIV-positive persons. Preventative vaccines against HPV
have been available for a decade. They are safe and efficacious
and their use in primary and secondary prophylaxis should be
suggested to HIV-positive patients, where suppressed HIV viral
load is associated with a higher level of antibodies induced by
vaccination. Until further data are available for HIV-positive
patients, a three-dose schedule is recommended for both adults
and children. Meanwhile, other therapeutic vaccines are in
development. In future, they could contribute to less aggressive
ablative therapy for HPV-associated lesions.
Clinical research and methodology
In the first of two methodological talks, Rodolphe Thiebaut
(Research Center ‘Bordeaux Population Health’ U1219, Bordeaux,
France) described how in silico clinical trials could add value to
existing drug development programmes. This computer-simulation
approach could be used in the development or evaluation of a
new drug, device or intervention, allowing efficiencies in the
selection and design of subsequent clinical trials. The approach
requires investigators to define a mathematical model that will
reasonably approximate the underlying mechanisms of interest,
which is then parameterised using existing information from a
variety of sources. These models also incorporate unmeasured
inter-individual variability. As a first example, he described how
models of viral dynamics could be used in the assessment of novel
ART strategies that would reduce the amount of individual drug
exposure, thus potentially reducing toxicity risk and costs. The
model findings suggested that while ART strategies that treated
individuals for 4 or 5 days out of every 7 may provide adequate
drug coverage to ensure maintenance of viral suppression (with
the ART regimens based on EFV/3TC plus a second NRTI), further
reduction in the number of days of treatment is likely to lead to
viral rebound. His second example illustrated how in silico models
could be used to identify the impact of different frequencies of
IL-7 administration on CD4 cell survival and proliferation. He
concluded by emphasising that while no model was ever perfectly
defined, some may provide useful information that could be used
to guide the design of future strategic treatment trials.
Caroline Sabin (University College London, London, UK) next
described the benefits and possible disadvantages of cohort studies
[58]. While randomised controlled trials are generally felt to be
the study design that provides the highest level of evidence, these
are not always feasible or practical. In such caseswhen it is impossible
to conduct a randomised trial (for example, when assessing the
impact of a lifestyle or behavioural exposure), cohort studies may
offer a good alternative design. These studies follow a group of
Figure 7. Estimate of number of HPV-related lesions/year worldwide
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individuals over time, identifying those who are and are not exposed
to a factor of interest and relating this exposure to outcomes.
However, whilst cohort studies are commonly reported in the
literature, they do have several limitations, particularly around the
possible presence of bias. Confounding, in particular, may have a
strong impact on the estimated association between exposure and
outcome.To illustrate this point, she provided examples of situations
where associations between HIV infection and a comorbidity or
biomarker have been confoundedby age and cytomegalovirus (CMV)
infection, respectively. In both cases, an apparent association
between HIV status and the outcome was attenuated after
adjustment for the confounder. These examples emphasise the
importance of consideration of the possibility that bias may have
been introduced as part of the study design, analysis or publication
process. She also noted that while appropriate statistical methods
may sometimes reduce the impact of bias, they may not always
be successful.
How to measure HIV-1 reservoirs
Alexander Pasternak (Laboratory of Experimental Virology,
Department of Medical Microbiology, Academic Medical Center,
Amsterdam, the Netherlands) discussed the important issue of how
to measure HIV-1 reservoirs and predict the outcome of ART
interruptions. He described the ideal assay that would include the
following characteristics: high sensitivity as it must be able to detect
rare events in a high background of uninfected cells; high
specificity; potential to distinguish replication-competent from
non-replication-competent reservoir; high precision with a large
dynamic range with the possibility to detect small changes in the
reservoir when monitoring in vivo curative interventions.
Dr Pasternak then reviewed the various methods that are available
to measure the HIV reservoir. The PCR-based methods for HIV
DNA (total or integrated) cannot distinguish replication-competent
from non-replication-competent virus, bearing in mind that the
majority (>90%) of the proviruses detected are defective and
therefore the size of the replication-competent reservoir is
overestimated. The quantitative viral outgrowth assay (qVOA) is
able to distinguish replication-competent from non-replication
competent virus but underestimates the size of the latent reservoir
[59]. The murine viral outgrowth assay (mVOA) which uses in vivo
amplification of replication-competent HIV may be more sensitive
than qVOA but is long, laborious, requires laboratory animals, and
is not quantitative (unless multiple mice are xenografted in the
LDA) [60]. Another type of assay, which includes the inducible
RNA transcription assays (i.e TILDA, iCARED, and others), still
overestimate the true size of the replication-competent reservoir
and partly detect defective provirus [61]. The HIV translation-
competent reservoir might be more specific than cell-associated
RNA alone but is laborious, requires many cells and still
overestimates the reservoir as gag expression is necessary but not
sufficient for replication-competence [62].
When looking at the results of a clinical randomised study of early
and temporary antiretroviral treatment in primary HIV infection
in the Netherlands, cell-associated HIV-1 unspliced RNA level
independently predicted both time to virological suppression and
time to virological rebound in patients treated with temporary early
ART [63]. Unspliced RNA, total viral DNA and the CD4+ T cell
count were measured before ART interruption. Unspliced RNA was
associated to time to viral rebound and warrants further exploration
as a predictor of post-treatment control in large-scale clinical trials
aimed at functional cure. Cell-associated HIV-1 multiply spliced
(MS) RNA level independently predicted disease progression (CD4+
T-cell loss) after interruption of early ART, while unspliced RNA
was not.
In conclusion when looking at reservoirs, HIV DNA represents a
marker of total reservoir that is mostly defective. Unspliced RNA
is a marker of the active reservoir (cells transcribing viral RNA).
It overestimates the latter but may correlate with functional
reservoir (cells that produce virus or can become reactivated upon
latency reversal). Multiply spliced (MS) RNA, a marker of the
‘hyperactive reservoir’ (cells with high MS RNA levels, a subset
of active reservoir). The relative size of this ‘hyperactive reservoir’
may drive HIV pathogenesis, determining the rate of CD4+ T cell
loss.
COREVIH session: the pathway of care for
people living with HIV
Guillaume Gras (CeGIDD 37, President of COREVIH Centre Val
de Loire, France) inaugurated this session explaining that the
chronicity of HIV infection combined with medical demographic
changes contribute to improvement of the care pathway.
A cooperation agreement between healthcare workers could lead
to changes in activity patterns. For example, consultations every
6 months alternately with a doctor and a nurse could be
implemented. The nurse could perform blood tests, clinical
measures, vaccinations, counselling, evaluation of risk factors
(cardiovascular, neurological, bones, tobacco use), prescriptions
and appointments, as well as record the visit. It is important to
notice that a high level of acceptability from patients is expected,
even if healthcare workers express some fears.
Roland Landman (Hôpital Bichat Claude Bernard SMIT IMEA,
INSERM U 1137, Paris, France) talked about therapeutic alleviation
or decreasing the pill burden in order to reduce toxicities,
drug–drug interactions, as well as health costs. Although many
studies are yet to report, dual-therapy is already recommended
in European and French guidelines for some combinations
(protease inhibitors/ritonavir+3TC, DTG + RPV) in virologically
suppressed patients (<50 copies/mL) for at least 6–24 months
respectively, with particular caution needed for monitoring HIV-1
DNA, archived genotypic mutations and patients’ adherence.
Results of pilot studies of discontinued regimens are rather
encouraging (90% success in 53 patients in the FOTO study, 87%
success in 113 patients in a Ugandan study, 100% success in
ICCARRE study). QUATUOR is an on-going multicentric French
ANRS study evaluating non-inferiority at week 48 between a 4
versus 7 day 3 drug ART regimen in virologically suppressed
patients.
Jean-Daniel Matthieu (Réseau Santé Marseille Sud, France)
concluded this session explaining his journey as a person living
with HIV and the help he had from the community network. He
talked about the impact of arguing with medical doctors and
healthcare workers and described how he fought for his life. He
highlighted the fact that patients should be actors in healthcare.
Electronic technology to improve HIV
management
Lynn Fiellin (Yale Center for Health and Learning Games, New
Haven, CT, USA) presented her original research about the future
of digital games for HIV prevention and care [64]. The purpose
of her presentation was to share two digital games that have been
developed and evaluated by the play2PREVENT Lab at Yale to
focus on risk reduction and HIV prevention, and HIV testing and
counselling. The first game, PlayForward: Elm City Stories
(PlayForward), is a 2-D graphic novel-style interactive videogame
that focuses on adolescents acquiring and practising skills to reduce
risk behaviours and gain knowledge and healthier attitudes and
intentions with the ultimate goal of HIV prevention. The impact
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of PlayForward on at-risk adolescents was recently rigorously
evaluated through a full-scale randomised controlled trial and
demonstrated a significant and persistent positive effect on
behavioural antecedents/health outcomes that are critical for HIV
prevention. A follow-up game, PlayForward: Test! was adapted from
the original game to have a greater focus on HIV testing and
counselling. This game has been pilot-tested and is undergoing
further expansion and will then be evaluated through a randomised
clinical trial.
What‘s up in PrEP
The subject of PrEP was covered during the first collaborative
symposium between the British HIV Association (BHIVA) and
ISHEID.
Rosalind Coleman (Joint United Nations Programme on HIV/
AIDS, Geneva, Switzerland) covered a regional review of PrEP
regulatory status and activity [65]. She explained that the
differences in the specific form of PrEP that is available to a
national level depends on international considerations, such as
active patents or the existence of national legislation that enables
TRIPS flexibilities to be exploited. This is why some programmes
may use originator TDF/FTC, some generic TDF/FTC and others
generic forms of TDX/FTC. The PrEP provision is handled
differently in each country. Only six countries have it reimbursed/
free at the point of delivery (Scotland, Wales, Sweden, France,
Belgium and Norway). In England, Portugal and the Netherlands
it is provided as part of a trial. In other countries, provision is less
co-ordinated. EACS recommendations include daily PrEP and, for
MSM, event driven PrEP is also an option. Dr Coleman reported
that the majority of individuals in Europe use it daily. Owing to
low rates of PrEP provision within national programmes, she
described high rates of internet purchasing. Internet purchasing
is well supported by a large community of activists who are highly
motivated and provide very useful materials and advice. She
cautions that this situation nonetheless may result in a lack of
follow-up, potential for resistance, side -effects and inadequate
dosing leading to new infections. ‘Generic access via the internet
is not a strategy’. She commended the high-level, targeted and
rapid roll-out of PrEP in New South Wales which led to a 35%
decline in state-wide HIV diagnoses in MSM, and a 44% decline
in early HIV infections in this population within one year of
enrolment. She noted that in a concentrated epidemic with high
testing and treatment coverage, PrEP scale-up has led to a rapid
decline in HIV transmission at the population level. She concluded
that while there is widespread PrEP demand, provision and access
across Europe are highly variable and often inadequate. She
identified PrEP as a contributor to the control of the HIV epidemic
where it is part of comprehensive and accessible HIV prevention
provision, including testing and treatment to viral suppression. She
urged countries to use all means possible to provide access to
affordable PrEP for people and populations at substantial risk of
HIV infection.
The second speaker, Brooke Nichols (Johannesburg, South Africa)
spoke on the cost-effectiveness of PrEP in the European context
[66]. She started by stating that when an infection is prevented,
there is saving of the associated lifetime costs of HIV infection.
This is estimated to equate to a ~€320,000 lifetime cost.
Effectiveness is reported as: quality-adjusted life years (QALYs)
gained or infections averted. These are generally calculated using
dynamic HIV transmission modelling, that is when PrEP is given
to a certain number of people, how many infections can we expect
to prevent? How many QALYs can we expect to gain? These
measures are affected by adherence and exposure risk which are
derived from PrEP trials. While widely debated, an intervention
is considered highly cost-effective if it is below the threshold of
GDP per capita per QALY gained. However, it also depends on
the willingness of a country to pay and on a country-specific QALY
threshold set. She cited the example of the Netherlands that may
be willing to spend €20,000/QALY gained, whereas Belgium may
be willing to pay €50,000/QALY gained. Dr Nichols reported that
PrEP cost-effectiveness has been demonstrated for MSM in
European countries with good treatment coverage. The majority
of studies on the MSM epidemic show cost-savings are possible
with generic pricing. She calls for more information on the epidemic
in IVDus. To the question of whether PrEP is affordable in Europe,
she replied that it will depend on healthcare systems structure,
financing and resource constraints at the country level but will
be more likely with generic pricing.
In summary, this lively symposium re-iterated the importance and
cost-effectiveness of PrEP and that more political will is needed
across most of Europe to implement this crucial and cost-effective
intervention and make it available to all who need it.
The expert patient
During this session, the experience of two individuals living with
HIV was shared with the audience. Xavier Rey Coquais
(Association ACTIF Santé, Université des Patients, Paris) elaborated
on the following question: ‘Is research more efficient while
involving expert patients? Or is it just political correctness?’
In a context where volunteers and healthcare providers are alone
with information circulating with delay, the action of creating
groups and generating expertise may be an efficient solution for
a better dissemination of information among health providers, rapid
and accurate feedback on adverse events, faster recruitment into
trials and as a result an improved access to therapy. Patient
communities may help enhance quality and security of care at
reduced cost for the healthcare system.
The second topic was entitled: ‘From activism to research: the
experience of a patient who became expert.’ Fabienne Hejoaka
(Marseille, France) described her life journey from the fear of dying
to the lessons that she drew from other people‘s HIV experience.
In 2012, she graduated with a PhD in social anthropology with
a thesis entitled: ‘Children and secrecy: living and growing up with
HIV in Burkina Faso’. In 2017, she went back to university to study
for a certificate in therapeutic education, a course founded by
Catherine Tourette-Turgis and a multidisciplinary team in 2009.
The purpose of her research was to include 50% of expert patients
with a recognition of experiential knowledge of patients, a
validation of competencies with a diploma. She showed the
importance of narration and testimonies leading to reflexivity,
taking distance from YOUR illness, to be able to communicate,
disclosing oneself and sharing experience, hearing others, and
giving advice to others. The paradox of the ‘healthy expert patient’
is a real engagement, a will to work with and to support other
patients.
Extracts from the movie ‘120 Beats per minute’, by Robin
Campillo, which tells the story of activists from ACT-UP Paris
before ART introduction, were shown.
This session closed the Conference with a poignant moment. All
participants, community members and healthcare providers, shared
together the certainty of the common battle for people living with
HIV, with those of us who are still here remembering those who
have left us prematurely.
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